Yahoo · Sep 9, 2026
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
AC
NASDAQ · ACIU
AC Immune S.A.
Healthcare · Biotechnology
$2.69
Down-$0.07 (-2.54%)
Updated Sep 11, 2026, 3:05 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 294.76M
- P/E ratio
- -3.11
- Dividend yield
- 0.00%
- 52-week range
- $2.10 – $3.49
- Volume
- 157.53K
- Avg. volume
- 714.24K
Price performance
ACIU price history
1M range · 20 trading sessions · Daily adjusted prices
ACIU closed at $2.69 after 20 trading sessions, up 4.67% for the selected period.
- Last close
- $2.69
- Period change
- +4.67%
- Period low
- $2.49
- Period high
- $2.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $2.74 | $2.77 | $2.68 | $2.69 | 157.53K |
| Sep 9, 2026 | $2.78 | $2.81 | $2.725 | $2.76 | 146.57K |
| Sep 8, 2026 | $2.82 | $2.85 | $2.77 | $2.78 | 100.87K |
| Sep 4, 2026 | $2.91 | $2.94 | $2.82 | $2.86 | 155.63K |
| Sep 3, 2026 | $2.85 | $3.00 | $2.85 | $2.93 | 171.77K |
| Sep 2, 2026 | $2.70 | $2.865 | $2.70 | $2.84 | 257.18K |
| Sep 1, 2026 | $2.62 | $2.68 | $2.58 | $2.68 | 103.47K |
| Aug 31, 2026 | $2.67 | $2.735 | $2.61 | $2.64 | 132.96K |
| Aug 28, 2026 | $2.73 | $2.77 | $2.65 | $2.65 | 105.71K |
| Aug 27, 2026 | $2.83 | $2.91 | $2.685 | $2.71 | 169.43K |
| Aug 26, 2026 | $2.94 | $2.98 | $2.77 | $2.85 | 269.06K |
| Aug 25, 2026 | $2.85 | $2.965 | $2.85 | $2.92 | 241.3K |
| Aug 24, 2026 | $2.91 | $3.00 | $2.7986 | $2.86 | 371.17K |
| Aug 21, 2026 | $2.66 | $2.945 | $2.65 | $2.90 | 442.01K |
| Aug 20, 2026 | $2.60 | $2.65 | $2.435 | $2.64 | 237.11K |
| Aug 19, 2026 | $2.60 | $2.69 | $2.565 | $2.58 | 280.71K |
| Aug 18, 2026 | $2.54 | $2.59 | $2.505 | $2.57 | 90.23K |
| Aug 17, 2026 | $2.49 | $2.565 | $2.4698 | $2.53 | 104.65K |
| Aug 14, 2026 | $2.58 | $2.58 | $2.4301 | $2.49 | 133.24K |
| Aug 13, 2026 | $2.59 | $2.645 | $2.55 | $2.57 | 217.31K |
Latest ACIU news
The latest Smart Investors Daily articles mentioning ACIU.
Stock researchCompany · Overview
ACIU research
Overview
Company profile and research snapshot.
Company profile
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | BTIG | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| May 4, 2026 | BTIG | Buy | — |
| Mar 16, 2026 | BTIG | Buy | — |
| Nov 4, 2025 | BTIG | Buy | — |
News briefing
Generated Sep 10, 2026, 9:01 PM
Why Is ACIU Down Today?
AC Immune shares declined 2.54% today amid a broader biotech sector backdrop where competing companies are capturing investor attention with clinical trial advances. While recent headlines focus on developments at rival firms like Spyre and Verastem, the lack of positive ACIU-specific news appears to be weighing on sentiment.
Bottom line: ACIU's 2.54% decline reflects competitive pressure in the biotech space and a relative lack of company-specific positive news, as investor attention shifts to peers with more recent clinical wins. Investors should monitor ACIU's pipeline progress closely, particularly any upcoming trial data or partnership announcements that could reignite confidence in the company's therapeutic candidates and competitive positioning.
Yahoo · Sep 8, 2026
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
Yahoo · Sep 7, 2026
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
Yahoo · Sep 4, 2026
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
